Cerebrolysin dosage protocol

What the compound is

Cerebrolysin is a drug that consists of a mixture of neuropeptides derived from purified porcine (pig) brain proteins (PMID 36979317). It is described as mimicking the biological functions of neurotrophic factors (PMID 35268364).

How it is thought to work

Cerebrolysin is considered to have neurotrophic and neuroprotective activity (PMID 31710397). It is also thought to possess neurorestorative properties (PMID 36979317, PMID 35268364). Studies suggest its mechanism involves the modulation of mitochondrial function and the CREB/PGC-1α pathway (PMID 41204270). This compound has a complex, multimodal, and pleiotropic mechanism of action (PMID 35268364).

What laboratory and animal studies report

Multiple experimental studies have demonstrated cerebrolysin's neuroprotective and neurorestorative properties in both in vitro (cell culture) and in vivo (animal) settings (PMID 36979317). In one animal study involving BALB/c mice, cerebrolysin treatment reversed anxiety-like behavior and cognitive dysfunction induced by ketamine. It also restored mitochondrial ATP levels and reduced reactive oxygen species (ROS) in the hippocampus, while upregulating CREB, p-CREB, and PGC-1α protein expression (PMID 41204270).

Human evidence so far

Cerebrolysin is a drug approved for use in human patients diagnosed with traumatic brain injury (TBI) (PMID 36979317). A meta-analysis of ten clinical studies involving 8749 patients with TBI found that cerebrolysin treatment was associated with a statistically significant change in Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) scores, suggesting beneficial effects on clinical outcomes (PMID 36979317). However, the treatment did not affect mortality of any cause or length of hospital stay (PMID 36979317).

For Alzheimer's disease (AD) in humans, an umbrella review indicated that cerebrolysin appears to be beneficial for cognitive functions, global performances, and activities of daily living in AD patients (PMID 34924395). For ischemic stroke in humans, cerebrolysin has shown to improve outcomes while preserving a promising safety profile (PMID 35268364). It is one of several agents used in neurorehabilitation clinics for stroke patients (PMID 38948647).

Regarding vascular dementia in humans, a Cochrane review identified six randomized controlled trials with 597 participants but yielded inconsistent results in its 2013 publication (PMID 31710397). The updated review aimed to incorporate new studies and methods for appraising evidence (PMID 31710397).

Open questions and limitations

For TBI, further multi-center studies are recommended to optimize dosing and time of administration for cerebrolysin (PMID 36979317). In ischemic stroke, an individual approach is recommended, identifying patients who would benefit most from neurotrophic therapy (PMID 36582161). While several agents are discussed for neurorehabilitation in stroke, there is ongoing debate regarding their efficacy and safety (PMID 38948647). A Cochrane review on cerebrolysin for vascular dementia reported inconsistent results (PMID 31710397).

Key terms explained

Neurotrophic factors are substances that support the survival, growth, and differentiation of neurons (nerve cells). Neuroprotection refers to strategies or substances that protect neurons from damage or death (PMID 40087248). Neurorestorative properties indicate the ability to promote the repair or regeneration of damaged neural tissue (PMID 36979317). Traumatic Brain Injury (TBI) is a complex injury to the brain that can result from a sudden blow or jolt to the head (PMID 40087248). Ischemic Stroke (IS) occurs when a blood vessel supplying blood to the brain is obstructed, leading to tissue damage (PMID 36582161). Alzheimer's Disease (AD) is a progressive neurological disorder that causes the brain to shrink and brain cells to die, leading to dementia (PMID 34924395).